
Opinion|Videos|January 2, 2025
Understanding Ruxolitinib’s Mechanism of Action in Atopic Dermatitis
Author(s)Omar Noor, MD, FAAD
The panelist discusses how ruxolitinib treats atopic dermatitis by inhibiting Janus kinase (JAK)1/JAK2 signaling pathways to reduce inflammation and alleviate symptoms of the skin condition.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Nearly Half of Female Psoriasis Patients Report IPV, Study Finds
3
Experts See Promise in AI for Atopic Dermatitis Care
4
New Analysis Finds Radiofrequency Microneedling Superior for Rosacea Erythema and Patient Satisfaction
5























